Authors: Wenbo Yu, Nga TH Truong, Ruhi Polara, Tessa Gargett, Melinda N Tea, Stuart M Pitson, Michaelia P. Cockshell, Claudine S. Bonder, Lisa M. Ebert, and Michael P. Brown
Clinical & Translational Immunology, 5 July 2024
Effective immunotherapies for glioblastoma are urgently needed. In this study, scientists describe the development of a novel fibroblast activation protein (FAP)-targeting CAR and demonstrate, for the first time, its potential as a promising therapeutic candidate for the treatment of glioblastoma. The team also highlighted the advantages of kinetic live-cell assays on Axion BioSystems’ Maestro Z analysis platform, which allowed them to reveal antigen nonspecific mechanisms that may play a key role in antitumor activity over time. According to the authors, “By using the novel Maestro Z instrument to track target cell destruction over several days, we allow CAR‐T cells the time required to be activated by CAR engagement and then deploy a range of cytotoxic mechanisms against antigen‐negative tumor cells."
